Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Treace Medical Concepts Inc

Healthcare US TMCI

4.395USD
-0.095(2.12%)

Last update at 2026-06-24T18:17:00Z

Day Range

4.364.73
LowHigh

52 Week Range

3.9227.41
LowHigh

Fundamentals

  • Previous Close 4.49
  • Market Cap319.96M
  • Volume910130
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-50.54200M
  • Revenue TTM196.03M
  • Revenue Per Share TTM3.18
  • Gross Profit TTM 114.31M
  • Diluted EPS TTM-0.88

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -42.81500M -20.55200M -3.66800M -4.26500M
Minority interest - - - -
Net income -47.29800M -24.61200M -6.44500M -5.10600M
Selling general administrative 33.00M 18.43M 6.54M 4.46M
Selling and marketing expenses 102.58M 64.47M 31.65M 25.79M
Gross profit 114.31M 76.59M 44.90M 31.79M
Reconciled depreciation 2.13M 0.69M 1.21M 0.79M
Ebit -34.84400M -16.51000M -0.89100M -3.53500M
Ebitda -31.80100M -15.80700M 0.32M -2.63100M
Depreciation and amortization 3.04M 0.70M 1.21M 0.90M
Non operating income net other -7.99800M -4.04200M - -
Operating income -34.84400M -16.51000M -0.89100M -3.53500M
Other operating expenses 176.68M 110.93M 56.51M 42.95M
Interest expense 4.40M 4.06M 2.78M 0.84M
Tax provision - - - -
Interest income 0.91M 0.02M - 0.11M
Net interest income -3.48800M -4.04200M -4.52300M -0.73000M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 4.48M 4.06M 2.78M 0.84M
Total revenue 141.84M 94.42M 57.37M 39.42M
Total operating expenses 149.16M 93.10M 44.04M 35.32M
Cost of revenue 27.52M 17.83M 12.47M 7.63M
Total other income expense net -7.97100M -4.04200M -2.77700M -0.73000M
Discontinued operations - - - -
Net income from continuing ops -42.84200M -20.55200M -3.66800M -4.26500M
Net income applicable to common shares -42.81500M -20.74800M -4.30800M -4.90500M
Preferred stock and other adjustments - 0.20M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 251.91M 159.02M 140.82M 41.81M 29.72M
Intangible assets 9.03M - - - -
Earning assets - - - - -
Other current assets 7.85M 3.62M 3.01M 0.59M 0.46M
Total liab 113.97M 98.50M 47.75M 41.03M 26.55M
Total stockholder equity 137.94M 60.53M 93.07M 0.78M 3.16M
Deferred long term liab - - 0.17M - -
Other current liab 31.79M 21.24M 14.15M 0.00100M 6.40M
Common stock 0.06M 0.06M 0.04M 0.03M 0.03M
Capital stock 0.06M 0.06M 0.04M 7.96M 7.96M
Retained earnings -134.24700M -84.72000M -41.90500M -21.35300M -17.68600M
Other liab - - - -0.00100M -
Good will 12.81M - - - -
Other assets - 0.15M - - -
Cash 12.98M 19.47M 105.83M 18.08M 12.14M
Cash and equivalents - - - - -
Total current liabilities 45.03M 30.25M 18.21M 11.60M 7.33M
Current deferred revenue - - - 7.54M -
Net debt 57.32M 49.12M -76.46800M 12.90M 7.08M
Short term debt 1.40M 0.34M - 1.79M -
Short long term debt - - - 1.79M -
Short long term debt total 70.30M 68.59M 29.36M 30.98M 19.22M
Other stockholder equity 271.96M 145.22M 134.93M 14.17M 12.88M
Property plant equipment - 15.34M 2.85M 0.83M 1.15M
Total current assets 198.36M 133.40M 137.97M 40.98M 28.57M
Long term investments - - - - -
Net tangible assets - 60.53M 93.07M -7.15900M -4.77400M
Short term investments 110.22M 61.78M - - -
Net receivables 38.06M 29.20M 18.57M 14.49M 10.41M
Long term debt 53.01M 52.71M 29.36M 29.19M 19.22M
Inventory 29.25M 19.33M 10.56M 7.82M 5.56M
Accounts payable 11.84M 8.67M 4.06M 2.27M 0.93M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.16M -0.02700M - -2.63600M -1.64100M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.04M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -84.72000M -41.90500M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.15M 0.15M - - -
Deferred long term asset charges - - - - -
Non current assets total 53.55M 25.62M 2.85M 0.83M 1.15M
Capital lease obligations 17.30M 15.88M - - -
Long term debt total - 52.71M 29.36M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -61.68000M -2.70500M -1.06900M -1.21100M
Change to liabilities 11.74M 1.79M 1.33M -0.23600M
Total cashflows from investing activities -76.51800M -2.70500M -1.06900M -1.21100M
Net borrowings -0.98900M -1.78800M 11.32M 20.00M
Total cash from financing activities 20.81M 107.65M 11.50M 19.74M
Change to operating activities 9.39M 4.19M 1.04M 3.76M
Net income -42.81500M -20.55200M -3.66800M -4.26500M
Change in cash -86.36000M 87.75M 5.94M 10.86M
Begin period cash flow 105.83M 18.08M 12.14M 1.28M
End period cash flow 19.47M 105.83M 18.08M 12.14M
Total cash from operating activities -30.64800M -17.19300M -4.49400M -7.67300M
Issuance of capital stock 0.00000M 107.61M - 0.00000M
Depreciation 2.13M 0.69M 1.21M 0.79M
Other cashflows from investing activities - - - -
Dividends paid - -7.93500M - -
Change to inventory -8.76900M -3.08800M -3.40200M -2.81300M
Change to account receivables -11.03900M -4.22600M -4.29100M -6.02200M
Sale purchase of stock 2.19M 7.93M - -
Other cashflows from financing activities 52.51M 1.83M 31.50M 19.74M
Change to netincome 8.72M 3.83M 3.06M 0.96M
Capital expenditures 14.84M 2.71M 1.07M 1.21M
Change receivables -11.03900M -4.22600M - -
Cash flows other operating 9.27M -2.41700M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -86.36000M 87.75M - -
Change in working capital -5.80900M -1.33000M -5.31900M -5.30800M
Stock based compensation 8.11M 3.41M 0.92M 0.81M
Other non cash items 7.73M 0.18M 0.22M 0.15M
Free cash flow -45.48600M -19.89800M -5.56300M -8.88400M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TMCI
Treace Medical Concepts Inc		 -0.095 2.12% 4.39 - - 3.93 5.33 3.65 -17.5068
ABT
Abbott Laboratories		 0.53 0.59% 91.06 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 4.65 1.50% 314.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.31 0.38% 80.32 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.845 1.85% 44.76 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Treace Medical Concepts Inc

100 Palmetto Park Place, Ponte Vedra, FL, United States, 32081

Key Executives

Name Title Year Born
Mr. John T. Treace CEO, Founder & Director 1972
Mr. Thomas E. Timbie Independent Director 1958
Mr. Mark L. Hair CPA Chief Financial Officer 1970
Mr. Aaron Berutti Sr. VP of Sales 1979
Mr. Terry W. Lubben Sr. VP of Operations 1965
Mr. Scot Elder Chief Legal & Compliance Officer and Corp. Sec. 1975
Dr. Sean F. Scanlan Ph.D. Sr. VP of Marketing 1982
Mr. Daniel E. Owens Chief HR Officer 1972
Mr. Jaime A. Frias Chief Bus. Devel. Officer 1962
Ms. Shana Zink Sr. VP of Clinical Affairs, Medical Education & Reimbursement NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.